Conclusion:
We report a case of a patient with a mechanical mitral heart valve
replacement and thrombocytopenia chemotherapy induced with a successful
bridging with fondaparinux. While
there is currently no literature for the use of fondaparinux in patients
with mechanical heart valves, this drug may offer an option for bridging
of such patients who cannot use heparin due to severe thrombocytopenia
and high thrombosis risk concomitantly. However, further randomized
trials are warranted to confirm both the safety and efficacy of this
agent in this population.